Clinical Trials Directory

Trials / No Longer Available

No Longer AvailableNCT04599647

EAP for the Treatment of Glioblastoma With PVSRIPO

Expanded Access Protocol for the Treatment of Glioblastoma With PVSRIPO

Status
No Longer Available
Phase
Study type
Expanded Access
Enrollment
Sponsor
Istari Oncology, Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers

Summary

This is an open-label, single-arm, non-randomized, intermediate-sized expanded access study evaluating the safety, efficacy, and tolerability of PVSRIPO delivered via intratumoral infusion, in subjects with glioblastoma (GBM) who are ineligible to participate in clinical study with PVSRIPO that is currently open to enrollment.

Conditions

Interventions

TypeNameDescription
BIOLOGICALPVSRIPOPVSRIPO (5x10\^7 TCID50) delivered intratumorally via convection enhanced delivery (CED).

Timeline

First posted
2020-10-23
Last updated
2022-06-29

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT04599647. Inclusion in this directory is not an endorsement.

EAP for the Treatment of Glioblastoma With PVSRIPO (NCT04599647) · Clinical Trials Directory